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Abstract
Cancer vaccines with optimal tumor-associated antigens show promise for anti-tumor immunotherapy. Recently, nano-sized
vesicles, such as exosomes derived from tumors, were suggested as potential antigen candidates, although the total yield of
exosomes is not sufficient for clinical applications. In the present study, we developed a new vaccine strategy based on
nano-sized vesicles derived from primary autologous tumors. Through homogenization and sonication of tumor tissues, we
achieved high yields of vesicle-bound antigens. These nanovesicles were enriched with antigenic membrane targets but
lacked nuclear autoantigens. Furthermore, these nanovesicles together with adjuvant activated dendritic cells in vitro, and
induced effective anti-tumor immune responses in both primary and metastatic melanoma mouse models. Therefore,
autologous tumor-derived nanovesicles may represent a novel source of antigens with high-level immunogenicity for use in
acellular vaccines without compromising safety. Our strategy is cost-effective and can be applied to patient-specific cancer
therapeutic vaccination.
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Introduction
Studies have demonstrated that antigens expressed on the
surface of cancer cells are recognized by the host immune systems
[1]. This concept has been used to develop cancer vaccines, which
involve active cancer immunotherapy that stimulates the patient’s
own immune system to destroy the tumor cells. Anti-tumor
immunotherapy has the potential to remove not only growing
tumors but also metastasized tumors with fewer adverse effects
than chemotherapy or radiation therapy [2]. However, the success
of cancer vaccines is often limited by a failure of the immune
system to recognize the cancer cells [3]. Since most cancer types
(,80%), including melanoma, develop via alterations to normal
host cells rather than infection, the optimal cancer vaccine should
enhance tumor-specific immune responses to recognize the cancer
as a foreign invader [4]. Therefore, one of the critical steps to
overcoming immune tolerance is to find tumor antigens with high
immunogenicity as well as wide expression of host-specificity [5].
The antigens that have been used in clinical trials include
shared tumor peptides or proteins, heat-shock proteins, tumor
cells, and apoptotic bodies [6]. Of these, the shared antigens, such
as tyrosinase and melan-A in the case of melanoma, are well-
defined and have broad specificity for melanoma patients [7].
However, vaccination with these known antigens is not suitable for
all melanoma patients, and it often results in poor immunogenicity
and low efficacy [8]. To overcome these limitations, whole
autologous tumors that contain both well-known and as yet
unknown antigens have been suggested as the best source of
patient-specific tumor antigens [9]. The use of autologous tumor
cells as antigens dates back to the 1950s [10], and has evolved
through various modifications, such as irradiation or genetic
transduction to generate expression of cytokines, costimulators,
and surrogate foreign antigens [11]. However, using whole cells as
vaccine antigens raises safety issues and the risk of adverse effects,
e.g., autoimmune diseases, due to inappropriate immune respons-
es, especially those triggered by nuclear autoantigens [12].
Therefore, from the clinical perspective, it is important to extract
from autologous tumors those antigens that have fewer adverse
effects and that stimulate strong anti-tumor immune responses.
Nano-sized vesicles that mimic the size and geometry of viruses
have been reported to induce potent immune responses in a
vaccination setting [13]. Application of nano-sized vesicular
antigens for cancer vaccine has several advantages over the use
of whole cells or soluble proteins, such as higher local
concentrations of the antigens, efficient uptake by antigen-
presenting cells, and efficient entry into the lymphatic drainage
system [14,15]. A potent nano-sized vesicular antigen source is the
exosome, which is a naturally secreted nano-sized vesicle with a
size of 30–150 nm [16]. Tumor-derived exosomes contain diverse
and distinct sets of cellular proteins, including membrane-bound
vesicular antigens and tumor-specific antigens [17]. Studies have
shown that tumor-derived exosomes efficiently induce anti-tumor
responses both in vitro and in vivo [18,19]. However, the clinical use
of exosomes in cancer vaccines is hindered by the difficulties
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low yield of exosomes per cell in culture [20,21].
In the present study, we present a tumor cell-derived and nano-
sized vesicular antigen complex, termed the nanovesicle (NV). We
purified NVs directly from autologous tumor tissues by homog-
enization and sonication. The NVs were enriched with tumor-
specific antigens, while the nuclear proteins were excluded. The
autologous tumor-derived NVs combined with adjuvant induced
strong immune responses in dendritic cells (DCs) in vitro and
showed anti-tumor effects in vivo against both residual and
metastasized tumors. We believe that our system for engineering
the production of the NVs from tumors provides a novel avenue of
research into cancer treatment.
Results
Preparation and characterization of autologous tumor-
derived NVs
To prepare NVs from autologous tumors, a melanoma tumor
was excised from the pre-established melanoma mouse model.
The tissue was ground to produce single cells, and disrupted by
homogenization. After removal of the nuclei by mild centrifuga-
tion, the supernatants were sonicated and re-centrifuged at
10,0006g to remove cell debris and mitochondrial fragments.
Thereafter, the vesicles were concentrated by sucrose cushion
centrifugation. The morphologically intact vesicles were further
purified using Optiprep buoyant density centrifugation, to remove
protein aggregates and denatured vesicles. The tyrosinase-
enriched NVs were floated at a density of 1.087 g/ml
(Figure 1A). We obtained 1.860.4 mg of NVs per ,1.5610
8
cells of autologous tumor tissue. Transmission electron microscopy
of the purified NVs revealed that most of the NVs were small and
had the closed vesicular form (Figure 1B). Dynamic light-scattering
analysis showed that the mean diameter of the tumor-derived NVs
was 101.6624.8 nm (Figure 1C), which is consistent with the
results of a previous study of tumor-derived exosomes [22]. To
validate and compare the presence of melanoma antigens in
tumor-derived NVs and exosomes, we isolated exosomes from
B16BL6 melanoma cells [23]. Western blotting analysis showed
that the NVs and exosomes contained similar levels of melanoma
antigens, such as tyrosinase and melan-A (Figure 1D). Compared
with whole cell lysates, the tumor-derived NVs were enriched for
melanoma antigens, but lacked nuclear proteins, e.g., histones
(Figure 1D).
Therapeutic vaccination with the tumor-derived NVs to
block tumor growth
We assessed the therapeutic effect of the NV vaccine on tumor
growth. The tumors were established in C57BL/6 mice by
subcutaneous injection of 5610
5 B16BL6 cells. When the tumors
Figure 1. Preparation and characterization of tumor-derived NVs. A. Western blot analysis of the melanoma antigen tyrosinase in fractions
of tumor-derived NVs obtained from the Optiprep density gradients. The density of each fraction was determined by measuring absorbance at
340 nm. B. Transmission electron micrograph of the NVs prepared from autologous melanoma tissues. Bar, 200 nm. C. Size distribution of NVs,
measured by dynamic light-scattering, shows a diameter range of 80–150 nm. D. Western blot detection of tyrosinase, melan-A, and histone in 10 mg
of whole cell lysate (WC), exosomes (EX), and NV.
doi:10.1371/journal.pone.0033330.g001
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3), the mice were
vaccinated therapeutically by intraperitoneal injection of the
antigens (NVs or whole cell lysates) with or without polyriboino-
sinic:polyribocytidylic acid (polyI:C). The mice were further
vaccinated on Days 14 and 21. Tumor growth was monitored
and measured every two to three days. Figure 2 shows that
melanoma growth was significantly lower in the group of mice
immunized with NVs plus polyI:C than in the PBS-treated
(P,0.01), NV-treated (P,0.01) or polyI:C-treated (P,0.01)
groups. The T/C ratio (see Materials and methods) was also
significant based on the National Cancer Institute standard
(,42%) in the group that received NVs plus polyI:C (T/C ratio,
34%). However, we found that using tumor whole cell lysates as
antigens (WC plus polyI:C) did not induce a significant suppressive
effect on tumor growth (P.0.05). Collectively, these results
indicate that tumor-derived NVs used as antigen-enriched
complexes confer efficient therapeutic anti-tumor effects in vivo.
Immune responses induced by the tumor-derived NVs
We verified the role of DCs in the induction of immune
responses to melanoma-derived NVs. Bone marrow-derived DCs
from the mice were treated with 10 mg/ml of dioctadecyl-
tetramethylindocarbocyanine perchlorate (DiI)-labeled NVs for
24 h. FACS analysis revealed the uptake of tumor-derived NVs by
DCs (Figure 3A). Moreover, incubation with NVs plus polyI:C
increased the levels of DC maturation/activation markers (i.e.,
CD40, CD80, and CD86), as compared with the PBS-treated and
NV-treated groups (Figure 3B). Furthermore, DCs treated with
NVs plus polyI:C produced high levels of the Th1 cytokine IL-
12p70, as compared with PBS (P,0.001), NV (P,0.001) or
polyI:C (P,0.05) treatment (Figure 3C). IL-12p70 was upregu-
lated by treatment with polyI:C alone in vitro (Figure 3C), as DCs
contain Toll-like receptor 3 [24]. To characterize further the anti-
tumor adaptive immune responses in vivo, splenocytes and serum
samples were isolated from the mice that were immunized with the
NVs and/or polyI:C once a week for a total of 3 weeks. Figure 3D
shows that in vitro re-stimulation of the isolated splenocytes with the
NVs significantly increased IL-12p70 secretion only in the group
immunized with NVs plus polyI:C (P,0.001). In contrast, the Th2
cytokine IL-4 was not detected in any of the groups (data not
shown). Moreover, when the humoral response was assessed by the
measurement of serum antibody levels, immunization of the mice
with NVs plus polyI:C increased Th1-associated antibody, IgG2a,
production as compared with the PBS (P,0.01), NV (P,0.05),
and polyI:C (P,0.05) treatments (Figure 3E). These results suggest
that vaccination with tumor-derived NVs primes Th1 immune
responses to the established melanoma.
Therapeutic vaccination with the tumor-derived NVs
against pulmonary metastases
We investigated the effect of vaccination with the autologous
tumor-derived NVs on the growth of metastasized tumors. The
pulmonary metastasis model was established by intravenous
injection into mice of 1610
5 B16BL6 cells. On Days 4, 8 and
12 post-injection, the mice were therapeutically immunized with
the NVs and/or polyI:C. On Day 14, the mice were euthanized,
and the lung surface tumor nodules were enumerated. As shown in
Figure 4A, the mice that were vaccinated with NV plus polyI:C
showed reduced numbers of metastasized lung colonies, as
compared with the PBS-treated (P,0.05), NV-treated (P,0.05),
and polyI:C-treated (P,0.05) groups. Histological analyses also
showed that the number and size of the metastasized colonies in
the mice immunized with NV plus polyI:C were lower than those
in PBS-treated, NV-treated, and polyI:C-treated mice (Figure 4B).
Discussion
Vaccination with autologous tumor-derived NVs exploits the
advantages of autologous tumors as an optimal source of tumor-
specific antigens. By deriving NVs directly from tumor tissues, we
increased the total yield of vesicular antigens more than 30- to 40-
fold, as compared with naturally produced exosomes, without the
need for cell line construction from tumor tissues. We obtained
about 2 mg of NVs from 1.5610
8 cells, and obtained 50 mgo f
exosomes from the same number of cells. The purified NVs
exerted more anti-tumor effects than whole cell lysates, which
contain mixtures of soluble and irregular types of membrane
antigens. This result is consistent with previous report that
exosome-bound antigens induce more potent antigen-specific,
anti-tumor immune responses than the soluble forms of the
antigens [25]. Therefore, it is important to manipulate the mode of
antigen secretion into a vesicular form for vaccination. Thus,
tumor-derived NVs may represent a valuable alternative to
exosomes. However, it will be necessary to compare the anti-
tumor effects of the tumor-derived NVs and exosomes in the near
future.
Improving the efficacy of the tumor-derived NV vaccine
requires the incorporation of an appropriate adjuvant [6]. To
elicit immunity against a syngeneic tumor, we used the Toll-like
receptor 3 agonist polyI:C as an adjuvant. We observed that
administration of the polyI:C with the tumor-derived NVs delayed
tumor growth synergistically and inhibited the B16 lung tumor
nodules in the therapeutic vaccination setting. Moreover, NVs
complexed with polyI:C induced DC maturation and activation in
vitro to produce IL-12, which can activate natural killer cells and
mediate Th1 immune responses [26]. Further studies are needed
to examine in greater detail the anti-tumor mechanisms of this
vaccine and whether T cell-mediated immune responses and
natural killer cells are involved in blocking tumor growth and
metastasis.
Vaccination with tumor-specific antigens and effective adju-
vants is a promising treatment option [6], although optimization of
tumor NV-based vaccines remains challenging. One way to
improve the efficacy of the NV-based vaccine is to use DCs [27].
DCs, which take up tumor-derived exosomes, can induce potent
anti-tumor effects on established mouse tumors [16]. Moreover,
Figure 2. Effect on primary tumor growth of therapeutic
vaccination with tumor-derived NVs. Mice (n=7 per group) that
were pre-established with B16BL6 melanoma of the skin received 10 mg
of antigens (NVs or whole cell lysates) with or without 50 mg polyI:C per
mouse. The mice were subjected to measurements of tumor growth.
WC, melanoma whole cell lysates. **P,0.01; ns, not significant.
doi:10.1371/journal.pone.0033330.g002
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have been shown to promote effective anti-tumor effects [28,29].
As an extension to these studies, the abilities of derivative vesicles
from DCs pulsed with the tumor-derived NVs to induce potent
anti-tumor immune responses could be studied. Therefore, the
efficacy of our NV-based system could be improved by adopting
the high-level immune potency of DCs.
In conclusion, the autologous tumor-derived NVs described
herein represent a novel source of cell-free cancer antigens.
Vaccination with the autologous tumor-derived NVs is versatile
and can be applied to diverse cancers, including melanoma. Our
tumor-derived NV vaccination strategy could be applied to all
patients who undergo surgical removal of the primary tumors.
Materials and Methods
Mice, cell lines and reagents
Six-week-old female C57BL/6 mice were purchased from
Jackson Laboratories (Bar Harbor, ME, USA). The mice were
bred in the pathogen-free facility at POSTECH, and all live animal
experiments were approved by the POSTECH Ethics Committee
(approval no. 2010-01-0006). The B16BL6 melanoma cell line was
maintained in Minimum Essential Medium (Invitrogen, Carlsbad,
CA, USA) that was supplemented with 10% (v/v) heat-inactivated
FBS (Gibco, Grand Island, NY, USA), 100 U/ml penicillin, and
100 mg/ml streptomycin, and grown at 37uCi n5 %C O 2. PolyI:C
(Calbiochem, San Diego, CA, USA) was used as the adjuvant.
Figure 3. Immune responses induced by tumor-derived NVs. A. C57BL/6 mouse-derived bone marrow DCs efficiently take up DiI-labeled NVs
(10 mg/ml), as assessed by FACS analysis. The numbers indicate mean fluorescence intensities. B. FACS analysis reveals that DCs upregulate the
expression of maturation markers CD40, CD80, and CD86 after 24 h of incubation with NVs (2 mg/ml) and polyI:C (10 mg/ml). The numbers in the
panels indicate mean fluorescence intensities. C. IL-12p70 levels in the supernatants of the cultured DCs, as assessed by ELISA. D. Splenocytes were
collected from the mice immunized with NVs (10 mg) and/or polyI:C (50 mg), and the levels of secreted IL-12p70 were determined after in vitro re-
stimulation with NVs. E. Serum samples were collected and analyzed by ELISA for the presence of anti-tumor IgG2a.* P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0033330.g003
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Tumors were surgically excised when they were approximately 1
to 2 cm in diameter. The tumor tissues were homogenized into
single cells and washed with PBS. The cell pellet (1.0–1.5610
8 cells)
was then resuspended in 6 ml of hypotonic solution [10 mM Tris-
Cl (pH 7.5), 0.5 mM MgCl2, protease inhibitor], incubated for
30 min on ice, and homogenized with 100 strokes in a Dounce
homogenizer with a tight-fitting pestle (Wheaton, Millville, NJ,
USA). Immediately thereafter, 2 ml of restoration buffer [10 mM
Tris-Cl (pH 7.5), 0.5 mM MgCl2, 600 mM NaCl] was added, to
adjust the tonicity. The homogenate was centrifuged at 5006g for
10 min to remove unlyzed cells and nuclei. The 7.8 ml of
supernatant was collected, and diluted with 2.2 ml of PBS, and
then sonicated usinga 40 kHzBranson2510 bath sonifier (Branson,
Danbury, CT, USA) for 30 min at 4uC. This suspension was
centrifuged at 10,0006g for 10 min at 4uC to removemitochondria,
celldebris,and nuclear fragments[29]. The supernatant was loaded
onto a sucrose cushion (0.1 ml of 2.0 M sucrose and 1 ml of 0.8 M
sucrose) for ultracentrifugation at 100,0006g for 2 h at 4uC, to
concentrate the vesicle-containing fraction. The pellet was resus-
pended in 4.8 ml of 30% Optiprep/HEPES (Axis-Shield PoC AS,
Oslo, Norway), and applied to the bottom of a step-density gradient
[3.0 ml of 20% Optiprep and 2.5 ml of 5% Optiprep in 10 mM
HEPES (pH 7.0), 150 mM NaCl]. After centrifugation at
200,0006g for 2 h at 4uC, ten fractions of equal volume were
collected from the top of the gradient. The protein concentration of
each fraction was determined with the Bradford dye assay (Bio-Rad
Laboratories, Hercules, CA, USA). The diameter of the tumor-
derived NVs was determined by dynamic light-scattering measure-
ments (Zetasizer Nano S; Malvern Instruments, Worcestershire,
UK). All fractions were stored at 280uC until use.
Preparation of B16BL6-derived exosomes
Exosomes were isolated from B16BL6 melanoma cells, as
previously described, with minor modifications [23]. Confluent
B16BL6 cells were washed with PBS and then grown in Minimum
Essential Medium (Invitrogen) that was supplemented with 10% of
exosome-depleted FBS [30]. After 24 h of incubation, the
supernatant was collected and serially centrifuged at 3006g for
10 min, 20006g for 10 min, and 10,0006g for 20 min. The pre-
cleared supernatant was ultracentrifuged at 100,0006g for 2 h. The
resulting pellet, which contained exosomes and possible contami-
nating proteins, was resuspended in 4.8 ml of 30% Optiprep/
HEPES, and applied to the bottom of an Optiprep gradient (3.0 ml
of 20% and 2.5 ml of 5% Optiprep/HEPES). After the tubes were
centrifuged at200,0006gfor2 h,tenfractionsofequalvolume were
collected from the top of the gradient. The purified exosomes
floating on fraction 3 (density,1.092) werecollected, and the protein
concentration was determined with the Bradford dye assay.
Preparation of tumor cell lysates
Tumor tissues that were surgically excised from a mouse were
ground into single cells and washed with PBS. The tumor cells
were immediately processed by freezing in liquid N2, followed
immediately by thawing at 37uC [31]. This procedure was
repeated three times in rapid succession.
Western blotting
Samples (10 mg) of the whole cell lysates and tumor-derived
NVs were separated by SDS-PAGE (10% resolving gel), and
transferred to a PVDF membrane. The blocked membrane was
probed with the tyrosinase, melan-A (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), or anti-histone antibody (Upstate
Biotechnology, Lake Placid, NY, USA), followed by HRP-
conjugated anti-mouse or anti-rabbit IgG (Santa Cruz Biotech-
nology), respectively. The immunoreactive bands were visualized
with a chemiluminescent substrate.
Transmission electron microscopy
The purified tumor-derived NVs were applied to 400-mesh
copper grids (EMS, Matfield, PA, USA), and negatively stained
Figure 4. Effect on metastatic tumor growth of therapeutic vaccination with tumor-derived NVs. Mice (n=5 per group) that were pre-
injected intravenously with B16BL6 melanoma cells were administered 10 mg of NVs with or without 50 mg of polyI:C per mouse. A. The B16
melanoma pulmonary metastases in the different treatment groups were counted. The data shown are from two independent experiments. *P,0.05.
B. Histologic sections of representative lung metastases. Arrows indicate the B16 melanoma mass in the lung. Mice immunized with NVs plus polyI:C
showed decreases in the number and size of metastasized melanomas. Original magnification 6200; H&E staining.
doi:10.1371/journal.pone.0033330.g004
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under the JEM1011 microscope (JEOL, Japan) at an acceleration
voltage of 100 kV.
Engraftment of melanoma onto mouse skin and
therapeutic vaccination
B16BL6 cells (5610
5) in 100 ml of PBS were subcutaneously
injected into the shaved skin of mice. Tumor growth was assessed
twice weekly by palpation. Tumor volume was measured with a
pair of calipers and calculated using the formula: 1/
26(length6width
2). For therapeutic vaccination, mice were
vaccinated intraperitoneally with tumor-derived whole cell lysates
(10 mg) or NVs (10 mg) with or without polyI:C (50 mg) every week
after a palpable tumor was established on Day 7. Tumor growth
inhibition, defined as the ratio of the median tumor volume for the
immunized group versus that for the control group, was calculated
as the T/C ratio using the formula: [(median tumor volume of
treated group)/(median tumor volume of control group)]6100.
The effective criterion for the T/C ratio according to the National
Cancer Institute standard is less than 42% [32].
Isolation of bone marrow-derived DCs
Bone marrow-derived DCs were purified from C57BL/6 mice
as described previously, with minor modifications [33]. Briefly,
bone marrow cells were harvested and cultured in RPMI1640
medium (Invitrogen) that was supplemented with 10% FBS,
100 U/ml penicillin, 100 mg/ml streptomycin, 50 mM 2-mercap-
toethanol, and 20 ng/ml GM-CSF (R&D Systems, Minneapolis,
MN, USA) at 37uCi n5 %C O 2. Every two days of culture, half of
the medium was removed and replaced with fresh complete
medium. On Day 7 of culture, non-adherent and loosely adherent
cells were harvested and used for the experiments.
DC uptake experiments
Tumor-derived NVs (50 mg) in 0.2 ml of PBS were incubated
with 5 mM of DiI (Molecular Probes, Eugene, OR, USA) for
20 min at room temperature. DiI-labeled NVs (10 mg/ml) were
treated to DCs grown in a 6-well plate (2610
6 cells/well). After
24 h incubation at 37uC, cells were collected from the plate. The
cells were washed twice with 1 ml of FACS buffer (2% FBS and
0.1% sodium azide in PBS), and then resuspended in 0.3 ml of
FACS buffer. The uptake of NVs by DCs was assessed by a
FACSCalibur flow cytometer using CellQuest software (BD
Biosciences, San Jose, CA, USA).
DC maturation and activation assay
DCs were seeded at a density of 1610
6 cells/well in a 24-well
plate, and incubated with 2 mg/ml of NVs and/or 10 mg/ml
polyI:C. The cells were collected after 24 h and stained with anti-
CD40, anti-CD80, and anti-CD86 antibodies (BD Biosciences), to
analyze the levels of cell surface markers by flow cytometry. The
conditioned media of the cultured cells were harvested for the
determination of IL-12p70 production using an ELISA kit (R&D
Systems) according to the manufacturer’s instruction.
Measurements of splenocyte cytokine levels and serum
antibody levels in mice immunized with tumor-derived
NVs
C57BL/6 mice were immunized intraperitoneally on Weeks 0,
1, and 2 with 10 mg of tumor-derived NVs and/or 50 mg polyI:C.
The control groups were immunized with PBS. One day after the
last immunization, the mice were euthanized. Splenocyte
suspensions were prepared and stimulated with 2 mg/ml of NVs.
The supernatants were harvested after 72 h, and the levels of
cytokines were assayed by ELISA. Serum samples from the mice
were used to determine the circulating antibody levels by ELISA.
Briefly, flat-bottom 96-well plates were coated overnight with 1 mg
of NV, blocked with 1% BSA, and incubated with a 1:10 dilution
of mouse serum for the detection of anti-NV IgG2a antibodies
(Bethyl Labs, Montgomery, TX, USA).
Engraftment of melanoma into the mouse lung and
therapeutic vaccination
Engraftment of melanoma into the lungs of mice was performed
by intravenous injection of B16BL6 cells (1610
5) in 100 ml of PBS.
For therapeutic vaccination, the mice were vaccinated intraper-
itoneally with NVs (10 mg) with or without polyI:C (50 mg) on
Days 4, 8, and 12. The melanoma metastases on the surfaces of
the lungs were counted 14 days post-challenge. These experiments
were carried out with groups of five mice and were repeated twice.
Histology
Excised tissues were fixed with 4% paraformaldehyde. The
tissues were embedded in paraffin and sectioned at 4-mm thickness.
The paraffin sections were deparaffinized with xylene and stained
with hematoxylin and eosin (H&E). Images were acquired using an
Olympus BX51 microscope.
Statistical analysis
Data are presented as mean values with standard errors.
Significant differences between the treatments were assessed using
the Student’s t-test. A P-value of ,0.05 was considered statistically
significant.
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